Skip to main content
Advertisement

Main menu

  • Home
  • Content
    • Current Issue
    • Publication Preview--Ahead of Print
    • Past Issue Archive
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
    • COVID-19 Content and Resources
  • For Authors
  • About Us
    • About AJNR
    • Editors
    • American Society of Neuroradiology
  • Submit a Manuscript
  • Podcasts
    • Subscribe on iTunes
    • Subscribe on Stitcher
  • More
    • Subscribers
    • Permissions
    • Advertisers
    • Alerts
    • Feedback
  • Other Publications
    • ajnr

User menu

  • Subscribe
  • Alerts
  • Log in

Search

  • Advanced search
American Journal of Neuroradiology
American Journal of Neuroradiology

American Journal of Neuroradiology

  • Subscribe
  • Alerts
  • Log in

Advanced Search

  • Home
  • Content
    • Current Issue
    • Publication Preview--Ahead of Print
    • Past Issue Archive
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
    • COVID-19 Content and Resources
  • For Authors
  • About Us
    • About AJNR
    • Editors
    • American Society of Neuroradiology
  • Submit a Manuscript
  • Podcasts
    • Subscribe on iTunes
    • Subscribe on Stitcher
  • More
    • Subscribers
    • Permissions
    • Advertisers
    • Alerts
    • Feedback
  • Follow AJNR on Twitter
  • Visit AJNR on Facebook
  • Follow AJNR on Instagram
  • Join AJNR on LinkedIn
  • RSS Feeds
Letter

Interaction Should Guide Management Decisions

E. Johansson and J. Salzer
American Journal of Neuroradiology May 2018, 39 (5) E57; DOI: https://doi.org/10.3174/ajnr.A5579
E. Johansson
aPharmacology and Clinical Neuroscience Umeå University Umeå, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for E. Johansson
J. Salzer
aPharmacology and Clinical Neuroscience Umeå University Umeå, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for J. Salzer
  • Article
  • Info & Metrics
  • References
  • PDF
Loading

It is with great interest that we read the recent article by Jadhav et al1 concerning subgroup assessments in the SWIFT PRIME trial, especially for collateral status. They reported, “Outcomes stratified by collateral status had a benefit with thrombectomy across all groups: none-to-fair collaterals (33% versus 0%), good collaterals (58% versus 44%), and excellent collaterals (82% versus 28%).” They also reported, “A beneficial effect of endovascular therapy was observed over IV tPA alone across all levels of collateral flow, with the greatest effect in patients with excellent collaterals (82% versus 28%, P = .008).”

The authors reported that benefit persisted across multiple subgroups, but they still concluded, “Overall, this report supports the selection of patients for intra-arterial therapy on the basis of favorable patient characteristics (small core, good collateral circulation).” We do not agree with this conclusion because these patient characteristics were, foremost, assessed for prognosis, not treatment effect. Tests for statistical interaction between the predictors (treatment allocation arm and subgroups defined post hoc) were not performed, making the interpretation of data difficult.

The value and role of interaction testing and why it is not appropriate to test for superiority of a treatment in single subgroups are well presented in a Lancet educational series.2 In short, interaction evaluates whether the combination of 2 predictors affects the outcome in other ways than expected by each variable alone. To test for superiority in single subgroups is inappropriate because both false-negative (sample size reduced) and false-positive (multiple testing) findings are possible.

In the current example, having treatment was better than not having treatment,3 and having good collaterals was better than having bad collaterals—both among those treated and among those not treated.1 Thus, it seems that treatment is effective regardless of collateral status, and no obvious interaction is observed. A reasonable alternative hypothesis to test would have been that those with poor collaterals would do poorly, both with and without treatment; thus, the subgroup affects the treatment effect, which would be the basis for an interaction. For the sake of argument, let us assume that these results instead came from a large sample, that formal interaction tests had been performed, and that no interaction was detected. In such circumstances, patient characteristics would have affected prognosis, but not treatment effect, an important distinction: To treat those with good collaterals will result in excellent outcome in the eyes of the interventionist (high share of recoveries), but to treat regardless of collateral status will create more patient benefit (because all benefit) but a worse outcome in the eyes of the interventionist (lower share of recoveries). We advocate that the latter is more relevant, but this is not consistent with the authors' conclusions.

However, given the current small sample of 109 patients, divided into 6 groups, the risk of false-negative findings for interaction is high. The finding that having good collaterals was associated with a better outcome in the IV tPA arm compared with having excellent collaterals in the IV tPA arm further supports the study being underpowered and findings possibly being spurious and/or the result of multiple testing.

We encourage the authors to merge their data on a patient level with those of other recent similar trials so that these analyses will be well-powered and meaningful. We advocate against clinical decision-making based on the current preliminary data.

Footnotes

  • Disclosures: Elias Johansson—UNRELATED: Grants/Grants Pending: Several grants totaling $520,000, all from nonprofit research bodies, the majority from the Swedish Government: Västerbotten County ($400,000), Neurological Research Fund at Umeå University Hospital, Northern Swedish Stroke Fund, National Swedish Stroke fund, Jeansson Foundation*; Royalties: text books, Comments: about $100–$200 annually in royalties for 2 book chapters in a stroke book in Swedish. Jonatan Salzer—UNRELATED: Grants/Grants Pending: Synapsys, Comments: nystagmus investigation equipment donated for research*; Stock/Stock Options: Eurocine Vaccines, SensoDetect, Comments: stocks worth $130 in 2 biomed starter companies making flu vaccines (Eurocrine Vaccines) and neuropsychiatric diagnostic equipment (Sensodetect)*. *Money paid to the institution.

References

  1. 1.↵
    1. Jadhav AP,
    2. Diener HC,
    3. Bonafe A, et al
    ; SWIFT PRIME Investigators. Correlation between clinical outcomes and baseline CT and CT angiographic findings in the SWIFT PRIME trial. AJNR Am J Neuroradiol 2017;38:2270–76 doi:10.3174/ajnr.A5406 pmid:29025724
    Abstract/FREE Full Text
  2. 2.↵
    1. Rothwell PM
    . Treating individuals 2: subgroup analysis in randomised controlled trials—importance, indications, and interpretation. Lancet 2005;365:176–86 doi:10.1016/S0140-6736(05)17709-5 pmid:15639301
    CrossRefPubMed
  3. 3.↵
    1. Saver JL,
    2. Goyal M,
    3. Bonafe A, et al
    ; SWIFT PRIME Investigators. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med 2015;372:2285–95 doi:10.1056/NEJMoa1415061 pmid:25882376
    CrossRefPubMed
  • © 2018 by American Journal of Neuroradiology
PreviousNext
Back to top

In this issue

American Journal of Neuroradiology: 39 (5)
American Journal of Neuroradiology
Vol. 39, Issue 5
1 May 2018
  • Table of Contents
  • Index by author
  • Complete Issue (PDF)
Advertisement
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on American Journal of Neuroradiology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Interaction Should Guide Management Decisions
(Your Name) has sent you a message from American Journal of Neuroradiology
(Your Name) thought you would like to see the American Journal of Neuroradiology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Interaction Should Guide Management Decisions
E. Johansson, J. Salzer
American Journal of Neuroradiology May 2018, 39 (5) E57; DOI: 10.3174/ajnr.A5579

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Interaction Should Guide Management Decisions
E. Johansson, J. Salzer
American Journal of Neuroradiology May 2018, 39 (5) E57; DOI: 10.3174/ajnr.A5579
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Purchase

Jump to section

  • Article
    • Footnotes
    • References
  • Info & Metrics
  • References
  • PDF

Related Articles

  • Reply:
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Crossref
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

Similar Articles

Advertisement

News and Updates

  • Lucien Levy Best Research Article Award
  • Thanks to our 2022 Distinguished Reviewers
  • Press Releases

Resources

  • Evidence-Based Medicine Level Guide
  • How to Participate in a Tweet Chat
  • AJNR Podcast Archive
  • Ideas for Publicizing Your Research
  • Librarian Resources
  • Terms and Conditions

Opportunities

  • Share Your Art in Perspectives
  • Get Peer Review Credit from Publons
  • Moderate a Tweet Chat

American Society of Neuroradiology

  • Neurographics
  • ASNR Annual Meeting
  • Fellowship Portal
  • Position Statements

© 2023 by the American Society of Neuroradiology | Print ISSN: 0195-6108 Online ISSN: 1936-959X

Powered by HighWire